Innovations in Personalized Cancer Therapy: Insights from the I-PREDICT Trial

The I-PREDICT trial shows tumor-DNA personalization of multi-drug regimens improves response and survival without increasing severe toxicity—a clinically actionable shift as precision combination therapy moves from concept toward routine practice.

The study was prospective and genomics-driven, using comprehensive tumor-DNA sequencing to define actionable alterations and guide drug selection. Investigators paired advanced molecular profiling with available FDA-approved agents, then assembled individualized multi-agent regimens and dosing rules for each patient based on tumor-specific biomarkers. This departs from prior one-size-fits-all strategies by enabling closer matching to each tumor’s unique alterations.

Patients whose therapies most closely matched their tumor mutations had higher response rates and longer survival on reported endpoints. The protocol used adaptive pairing to assemble individualized drug combinations from approved agents with prespecified starting doses and escalation rules. Notably, matched regimens did not increase severe adverse events, indicating personalization did not compromise safety.

Key Takeaways:

• I-PREDICT provides prospective evidence that tumor‑DNA–guided, individualized combination regimens improve response and survival without more severe toxicity, supporting broader clinical adoption of tumor‑DNA personalization.
• Patients with advanced, refractory, or high‑risk cancers stand to benefit most; multidisciplinary teams should plan for increased demand on molecular‑testing pathways and joint decision-making.
• Expect earlier specimen‑collection workflows and routine tumor‑board review of molecular matches, plus active monitoring of implementation outcomes and pathway performance as programs scale.